Clinical trials: Adult Atopic Dermatitis, open to volunteers
Atopic Dermatitis
Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
This is a randomized, placebo-controlled and double-blind study to evaluate the efficacy, pharmacokinetics, and Safety of repeat subcutaneous doses of FB825 in adults with moderate-to-severe atopic dermatitis.
- Trial name
- NCT06397911
- Testing
- FB825
- Where
- 16 sites in United States, Taiwan
- Volunteers
- 114 people
- Sponsor
- Oneness Biotech Co., Ltd.
Atopic Dermatitis
A Study of Two Different Formulations of 611 in Healthy Adult Subjects in China
The main purpose of this study is to compare two different formulations (mixtures) of 611 in healthy participants. This study will compare how much of each formulation gets into the blood stream.
- Trial name
- 611 (NCT07042113)
- Testing
- new formulations of 611, existing formulations of 611
- Where
- 2 sites in China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Atopic Dermatitis
A Multicenter, Randomized, Double-blind, Vehicle Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Gel in Adult Subjects With Mild to Moderate Atopic Dermatitis
This is a multicenter, randomized, double-blind, vehicle controlled phase II clinical study to evaluate the efficacy and safety of VC005 gel in adult subjects with mild to moderate atopic dermatitis
- Trial name
- NCT07598383
- Testing
- VC005 group
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
Atopic Dermatitis
A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema
The purpose of this study is to find out how well tilrekimig works, how safe it is, and how it affects the body in adults and adolescents with moderate to severe atopic dermatitis (eczema).
- Trial name
- Tilrek (NCT07783425)
- Testing
- Tilrekimig, Dupilumab
- Where
- 32 sites in United States, Japan
- Volunteers
- 1,375 people
- Sponsor
- Pfizer
Atopic Dermatitis
Effectiveness of Upadacitinib and Biologics for the Achievement of Minimal Disease Activity in Adults With Moderate-to-Severe Atopic Dermatitis (RAMpUp)
Atopic dermatitis (AD) is a common, chronic, inflammatory skin disease with a significant impact on patients' health-related quality of life.
- Trial name
- RAMpUp (NCT07741838)
- Volunteers
- 900 people
- Sponsor
- AbbVie
AD
A Phase I Study of SSGJ-716 in Healthy Adults and Participants With Moderate-to-Severe Atopic Dermatitis
The purpose of this Phase 1 study is to evaluate the safety and tolerability of a new investigational drug called SSGJ-716 in healthy adults and in participants with moderate-to-severe atopic dermatitis (AD).
- Trial name
- NCT07693738
- Testing
- SSGJ-716
- Where
- China
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Atopic Dermatitis
A Study to Assess the Efficacy and Safety of PG-011 Gel in Adolescents and Adults With Atopic Dermatitis
This is a Multicenter, Randomized, Double-blind, Placebo-controlled seamless and adaptive-designed phase IIb/III study to Assess the Efficacy and Safety of topical use of PG-011 Gel in adolescents and Adults With Atopic…
- Trial name
- NCT06587685
- Testing
- PG-011Gel, Vehicle
- Where
- China
- Volunteers
- 472 people
- Sponsor
- Prime Gene Therapeutics Co., Ltd.
Atopic Dermatitis
Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares
This study will collect skin measurements from people with atopic dermatitis (AD) using the investigational Nevisense Go device.
- Trial name
- Detect-AD (NCT07645820)
- Testing
- Nevisense electrical impedance spectroscopy
- Where
- 13 sites in United States
- Volunteers
- 450 people
- Sponsor
- Castle Biosciences Incorporated
Atopic Dermatitis (AD)
Treatment of Moderate-to-Severe Atopic Dermatitis With Ivarmacitinib in Adolescents and Adults
Atopic dermatitis (AD) is a skin condition characterized by a rash and itching, resulting from skin inflammation. Ivarmacitinib is an approved medication for treating AD.
- Trial name
- NCT07276620
- Testing
- Ivarmacitinib Sulfate Tablets
- Volunteers
- 1,000 people
- Sponsor
- Xiangya Hospital of Central South University
Atopic Dermatitis, Eczema
A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis.
The purpose of this study is to learn about the safety and effects of Abrocitinib in the real-life clinical setting given for the treatment of moderate to severe atopic dermatitis.
- Trial name
- ADAIR (NCT05689151)
- Testing
- Abrocitinib
- Where
- 30 sites in France
- Volunteers
- 183 people
- Sponsor
- Pfizer
Moderate-to-severe Atopic Eczema
TREAT NL (TREatment of ATopic Eczema, the Netherlands) Registry: Dutch National Registry for Patients With Moderate-to-severe Atopic Eczema on Photo- or Systemic Therapies
The TREAT NL (TREatment of ATopic eczema, the Netherlands) registry is a national registry for children and adults with moderate-to-severe atopic eczema aiming to gather data on their prescribed photo- and systemic…
- Trial name
- TREAT NL (NCT03621137)
- Testing
- No study-specific intervention
- Where
- Netherlands
- Volunteers
- 500 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Atopic Dermatitis (AD)
A Phase 3 Trial to Demonstrate the Superiority of 1% OPA-15406 Foam to the Vehicle in Adult Patients With Atopic Dermatitis
To investigate the superiority of 1% OPA-15406 foam to the vehicle in adult patients with atopic dermatitis (AD).
- Trial name
- NCT07173478
- Testing
- OPA-15406, Vehicle
- Where
- Japan
- Volunteers
- 156 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Mild to Moderate Atopic Dermatitis
A Study to Evaluate the Efficacy and Safety of IN-115314 Ointment in Mild to Moderate Atopic Dermatitis Adult Patients
This study aims to evaluate the efficacy and safety of IN-115314 Ointment in mild to moderate atopic dermatitis adult patients
- Trial name
- NCT07073677
- Testing
- IN-115314 Ointment 1%, IN-115314 Ointment 3%
- Where
- South Korea
- Volunteers
- 162 people
- Sponsor
- HK inno.N Corporation
Moderate to Severe Atopic Dermatitis
Phase III Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis
This clinical trial is a multicenter, randomized, double-blind, controlled phase III clinical study
- Trial name
- NCT06723080
- Testing
- VC005 low dose group, VC005 high dose group
- Where
- China
- Volunteers
- 480 people
- Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
Atopic Dermatitis, Emollients
Double-blind, Randomized, Non-inferiority Trial in Atopic Dermatitis: Comparison of Lipikar Balm and Relipid+ Balm in the Treatment of Mild to Moderate Atopic Dermatitis in Children and Adults
The therapeutic cornerstone for mild to moderate forms of atopic dermatitis (AD) relies on the combination of topical corticosteroids and emollients.
- Trial name
- AIMSI (NCT07358000)
- Testing
- Baume Relipid+
- Where
- France
- Volunteers
- 86 people
- Sponsor
- University Hospital, Caen
Moderate to Severe Atopic Dermatitis
Efficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis.
Atopic dermatitis is an ongoing condition that causes skin irritation, redness, and itchiness. Treatments are usually topical - applied to the skin (e.g., moisturisers or medicated creams) - but a wider variety of systemic…
- Trial name
- NCT06239311
- Testing
- Methotrexate
- Where
- 30 sites in Czechia, France and 2 more
- Volunteers
- 277 people
- Sponsor
- medac GmbH
Atopic Dermatitis
A Phase Ⅲ Comparative Study of QL2108 to Dupixent®
It is a multicenter randomized, double-blinded, parallel, positive-controlled, Phase Ⅲ comparative study to evaluate the efficacy and safety of QL2108 to Dupixent® in adult subjects with moderate-to-severe atopic dermatitis.
- Trial name
- NCT06884891
- Testing
- QL2108 injection, Dupixent®
- Volunteers
- 520 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Hidradenitis Suppurativa, Atopic Dermatitis
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
Hidradenitis suppurativa (HS) and atopic dermatitis (AD) are chronic inflammatory skin diseases that lead to the development of skin lesions and symptoms such as pain and discomfort.
- Trial name
- NCT06524635
- Testing
- Lutikizumab
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- AbbVie
Atopic Dermatitis
Frequency of Palpebral Involvement in Adult With Atopic Dermatitis
Atopic dermatitis is a common inflammatory skin disease, resulting from genetical, immunological and environmental factors. Head and neck are among the most frequent involved areas, almost 50% in adult patients according to most…
- Trial name
- PAUPIAD (NCT04826744)
- Testing
- Standard dermatology consultation
- Where
- 2 sites in France
- Volunteers
- 550 people
- Sponsor
- University Hospital, Lille
Atopic Dermatitis, Atopic
A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
This is a phase 2b, multicenter, randomized, double-blind, placebo-controlled study.
- Conditions
- Atopic Dermatitis, Atopic, Dermatitis, Dermatitis, Atopic
- Trial name
- NCT07599813
- Testing
- Camoteskimab
- Where
- 85 sites in United States, Bulgaria and 6 more
- Volunteers
- 280 people
- Sponsor
- Apollo Therapeutics Ltd